• Contract signed with: 
    Montpellier Cancer Institute,  France

  • Principal investigator:
    Marc Ychou

Quantification of hPG80 in the blood of patients with adenomatous and hyperplastic polyps and early stage colorectal cancer

Last updated: August 3, 2020

hPG80, a new blood based biomarker

When progastrin is maturated into gastrin, it is released from the cells. 

When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion.

When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG80.

This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG80, which can be detected in the blood of cancer patients. 

Show the presence or absence of hPG80 in the blood of patients with adenomatous polyps or with early colorectal cancer and establish the discriminative accuracy of hPG80 as a biomarker of these pathologies.

Correlate hPG80 levels with cancer stage.

Cancer patients samples were obtained from SIRIC (Montpellier, FRANCE). 

Analyzes were performed within Eurobiodev facility (Montpellier, FRANCE).

This retrospective study was approved by Montpellier cancer institute scientific council (ICM-CORT). 

Approval date and number: 13/11/2017 (ICM-CORT-2017-23) 96 patients were included in the study.


Healthy blood donors samples were obtained from the French blood agency (EFS, Montpellier, FRANCE).

Analyzes were performed within Eurobiodev facility (Montpellier, FRANCE).

Approval date and number: 17/07/2017 (21PLER2017-0019) 80 non-fasting healthy donors were included in the study.

The presence of hPG80 in early colorectal cancer stages was confirmed. 

Median hPG80 levels in CRC early stages patients were significantly higher than those in healthy blood donors (p< 0.0001) (Figure 1). 


Median hPG80 concentration was 0.23 pM (IQR 0.00-0.80 pM) in control population, against 2.315 pM (IQR 0.64-3.69 pM), 2.26 pM (IQR 0.70-9.60 pM), and 5.46 pM (IQR 1.67-9.945 pM) in patients with preneoplasic lesions, CRC stage 1 or CRC stage 2, respectively (Figure 1).


There is a significant increase in hPG80 blood levels from adenomatous polyps to stage 2 colorectal cancer.

Figure 1. 


Comparison of hPG80 concentrations between healthy blood donors (n=80) and cancers patients, preneoplasic lesions (n=24), stage 1 CRC (n=23), stage 2 CRC (n=49).


Representation in box and Whiskers (2.5-97.5 percentile, dots are outliers).


Two-tailed Mann-Whitney test; ***, p< 0.001; *, p< 0.05.

The diagnostic discriminative accuracy of hPG80 levels was estimated using Receiver Operating Characteristics (ROC) curves in patients with preneoplasic lesions, patients with stage 1 CRC or patients with stage 2 CRC, compared to healthy blood donors control cohort.

The diagnostic discriminative accuracy estimated by the ROC AUC were 0.80 (95% CI: 0.69 to 0.91) for patients with preneoplasic lesions; 0.825 (95% CI: 0.72 to 0.93) for patients with stage 1 CRC; and 0.89 (95% CI: 0.82 to 0.95) for patients with stage 2 CRC, compared to the blood donor control group (Figures 2, 3 and 4).

hPG80 is detected with a very good accuracy in the blood of patients with an adenomatous polyp or with a stage 1 or 2 colorectal cancer.


It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detect the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg













Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.


For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.


The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved